HNP-1 Reverses Hypertensive Left Ventricular Hypertrophy by Inhibiting the NF-кB Signaling Pathway
Background: Human neutrophil peptide-1 (HNP-1) is a commonly investigated therapeutic agent. However, its role in hypertensive left ventricular hypertrophy (HLVH) remains unclear. Methods: We measured HNP-1 levels in patients with hypertension and treated HLVH rat and H9c2 cell hypertrophy models...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Compuscript Ltd
2023-08-01
|
| Series: | Cardiovascular Innovations and Applications |
| Online Access: | https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0057 |
| _version_ | 1827636161802141696 |
|---|---|
| author | Xiaorong Duan Zhenqiu Yu |
| author_facet | Xiaorong Duan Zhenqiu Yu |
| author_sort | Xiaorong Duan |
| collection | DOAJ |
| description | Background: Human neutrophil peptide-1 (HNP-1) is a commonly investigated therapeutic agent. However, its role in hypertensive left ventricular hypertrophy (HLVH) remains unclear. Methods: We measured HNP-1 levels in patients with hypertension and treated HLVH rat and H9c2 cell hypertrophy models with HNP-1. Cardiomyocyte hypertrophy indexes (i.e., single-cell surface area, left ventricular fibrosis area, BNP levels, and β-MHC levels) were measured with hematoxylin-eosin and Masson’s trichrome staining and WB. NF-кB signaling factors (i.e., IKKβ, p-IKKβ, IкBα, p-IкBα, p65, and p-p65) were measured with WB and qPCR. Finally, inflammatory factors (i.e., IL-6, IL-1α, and TNF-α) were measured with ELISA. Results: HNP-1 levels were lower in the exposure than the control groups (M (95% CI), 48.83 (45.64–52.26) vs. 59.03 (55.62–62.54), P = 0.000). Diminished HNP-1 was associated with HLVH occurrence in patients. HLVH rat and H9c2 cell hypertrophy models revealed elevated cardiomyocyte hypertrophy indexes and NF-кB signaling and inflammatory factors. However, each HNP-1 treatment group showed lower levels of the aforementioned indices than were observed in the model groups. Conclusion: Diminished HNP-1 is a risk factor for HLVH. HNP-1 treatment may reverse HLVH by inhibiting NF-кB signaling pathways. |
| first_indexed | 2024-03-09T15:38:13Z |
| format | Article |
| id | doaj.art-a01ec1ac2de44ed8b308c7080d602f1c |
| institution | Directory Open Access Journal |
| issn | 2009-8618 2009-8782 |
| language | English |
| last_indexed | 2024-03-09T15:38:13Z |
| publishDate | 2023-08-01 |
| publisher | Compuscript Ltd |
| record_format | Article |
| series | Cardiovascular Innovations and Applications |
| spelling | doaj.art-a01ec1ac2de44ed8b308c7080d602f1c2023-11-25T17:00:13ZengCompuscript LtdCardiovascular Innovations and Applications2009-86182009-87822023-08-018195710.15212/CVIA.2023.0057HNP-1 Reverses Hypertensive Left Ventricular Hypertrophy by Inhibiting the NF-кB Signaling PathwayXiaorong DuanZhenqiu YuBackground: Human neutrophil peptide-1 (HNP-1) is a commonly investigated therapeutic agent. However, its role in hypertensive left ventricular hypertrophy (HLVH) remains unclear. Methods: We measured HNP-1 levels in patients with hypertension and treated HLVH rat and H9c2 cell hypertrophy models with HNP-1. Cardiomyocyte hypertrophy indexes (i.e., single-cell surface area, left ventricular fibrosis area, BNP levels, and β-MHC levels) were measured with hematoxylin-eosin and Masson’s trichrome staining and WB. NF-кB signaling factors (i.e., IKKβ, p-IKKβ, IкBα, p-IкBα, p65, and p-p65) were measured with WB and qPCR. Finally, inflammatory factors (i.e., IL-6, IL-1α, and TNF-α) were measured with ELISA. Results: HNP-1 levels were lower in the exposure than the control groups (M (95% CI), 48.83 (45.64–52.26) vs. 59.03 (55.62–62.54), P = 0.000). Diminished HNP-1 was associated with HLVH occurrence in patients. HLVH rat and H9c2 cell hypertrophy models revealed elevated cardiomyocyte hypertrophy indexes and NF-кB signaling and inflammatory factors. However, each HNP-1 treatment group showed lower levels of the aforementioned indices than were observed in the model groups. Conclusion: Diminished HNP-1 is a risk factor for HLVH. HNP-1 treatment may reverse HLVH by inhibiting NF-кB signaling pathways.https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0057 |
| spellingShingle | Xiaorong Duan Zhenqiu Yu HNP-1 Reverses Hypertensive Left Ventricular Hypertrophy by Inhibiting the NF-кB Signaling Pathway Cardiovascular Innovations and Applications |
| title | HNP-1 Reverses Hypertensive Left Ventricular Hypertrophy by Inhibiting the NF-кB Signaling Pathway |
| title_full | HNP-1 Reverses Hypertensive Left Ventricular Hypertrophy by Inhibiting the NF-кB Signaling Pathway |
| title_fullStr | HNP-1 Reverses Hypertensive Left Ventricular Hypertrophy by Inhibiting the NF-кB Signaling Pathway |
| title_full_unstemmed | HNP-1 Reverses Hypertensive Left Ventricular Hypertrophy by Inhibiting the NF-кB Signaling Pathway |
| title_short | HNP-1 Reverses Hypertensive Left Ventricular Hypertrophy by Inhibiting the NF-кB Signaling Pathway |
| title_sort | hnp 1 reverses hypertensive left ventricular hypertrophy by inhibiting the nf кb signaling pathway |
| url | https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0057 |
| work_keys_str_mv | AT xiaorongduan hnp1reverseshypertensiveleftventricularhypertrophybyinhibitingthenfkbsignalingpathway AT zhenqiuyu hnp1reverseshypertensiveleftventricularhypertrophybyinhibitingthenfkbsignalingpathway |